Stratec (SBS) Q3 2024 earnings summary

Executive summary

• Nine-month 2024 sales declined 6.1% year-over-year to €176.3 million, mainly due to lower demand for molecular diagnostics systems and postponed deliveries, while service parts and consumables saw significant growth.

• Adjusted EBIT for the nine months was €14.8 million, with a margin of 8.4%, slightly below last year, reflecting efficiency and earnings enhancement measures.

• Gross margin improved year-over-year despite lower economies of scale and suboptimal product mix, due to efficiency measures.

• Management expects significant sales and earnings improvement in Q4 2024 from new orders and postponed deliveries, aiming to meet full-year earnings guidance.

• Market position strengthened in Asia-Pacific and the U.S. following the Natech acquisition, with initial sales synergies realized.

Financial highlights

• Adjusted EBITDA for 9M 2024 was €26.3 million, margin 14.9% (+40 bps); adjusted EBIT was €14.8 million, margin 8.4% (-20 bps); adjusted consolidated net income was €8.1 million, down 16.5%.

• Q3 sales were €57.2 million, down 8.7% year-over-year; Q3 adjusted EBIT margin was 8.8%.

• Free cash flow improved to €13 million, driven by lower receivables and tax refunds.

• Net working capital improved to €109 million, mainly due to lower trade receivables.

• Net debt increased slightly to €119.4 million; equity ratio improved to 50.5%.

Outlook and guidance

• Sales for FY 2024 expected to remain stable or decline slightly; adjusted EBIT margin guidance confirmed at 10.0% to 12.0%.

• Q4 2024 anticipated to show significant improvement in sales and earnings due to new orders and realization of postponed deliveries.

• Investment in tangible and intangible assets projected at 6.0% to 8.0% of sales.

• Inventory levels expected to peak at year-end, with reversal and positive cash flow impact from 2025.

• Management is cautious for 2025, expecting gradual recovery but not a material rebound in molecular diagnostics.